| Diabetes Mellitus, Non-Insulin-Dependent
Glyxambi vs Tradjenta
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Glyxambi vs Tradjenta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTradjenta has a higher rate of injection site reactions vs Glyxambi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tradjenta but not Glyxambi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Glyxambi
Tradjenta
At A Glance
Oral
Daily
SGLT2 inhibitor / DPP-4 inhibitor
Oral
Daily
DPP-4 inhibitor
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Cardiovascular Diseases
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Diabetes Mellitus, Non-Insulin-Dependent, Cardiovascular Diseases 10 mg empagliflozin/5 mg linagliptin once daily in the morning, with or without food; may increase to 25 mg empagliflozin/5 mg linagliptin once daily for additional glycemic control; not recommended with eGFR less than 30 mL/min/1.73 m2; withhold at least 3 days prior to surgery or procedures associated with prolonged fasting.
Diabetes Mellitus, Non-Insulin-Dependent 5 mg orally once daily, with or without food.
Contraindications
- Hypersensitivity to empagliflozin, linagliptin, or any excipient in GLYXAMBI (including anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity)
- Hypersensitivity to linagliptin or any excipient in TRADJENTA, including reactions such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity
Adverse Reactions
Most common (>=5%) Urinary tract infection, nasopharyngitis, upper respiratory tract infection
Serious Diabetic ketoacidosis, pancreatitis, volume depletion, urosepsis, pyelonephritis, necrotizing fasciitis of the perineum, genital mycotic infections, hypoglycemia with insulin or insulin secretagogues, lower limb amputation, hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid, heart failure
Postmarketing Acute pancreatitis including fatal pancreatitis, constipation, mouth ulceration, stomatitis, anaphylaxis, angioedema, exfoliative skin conditions, necrotizing fasciitis of the perineum, urosepsis, pyelonephritis, ketoacidosis, rhabdomyolysis, acute kidney injury, bullous pemphigoid, rash, urticaria
Most common (>=2%) Nasopharyngitis, diarrhea, cough
Serious Pancreatitis, hypoglycemia with concomitant insulin or insulin secretagogues, hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid, heart failure
Postmarketing Acute pancreatitis including fatal pancreatitis, mouth ulceration, stomatitis, anaphylaxis, angioedema, exfoliative skin conditions, rhabdomyolysis, severe and disabling arthralgia, bullous pemphigoid, rash
Pharmacology
Empagliflozin is a SGLT2 inhibitor that reduces renal glucose reabsorption by inhibiting the predominant transporter responsible for filtered glucose reabsorption, thereby increasing urinary glucose excretion; linagliptin is a DPP-4 inhibitor that increases active incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and reducing glucagon levels.
DPP-4 inhibitor; linagliptin reversibly inhibits DPP-4, the enzyme that degrades incretin hormones GLP-1 and GIP, thereby increasing active incretin concentrations, stimulating glucose-dependent insulin release from pancreatic beta cells, and reducing glucagon secretion from pancreatic alpha-cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Glyxambi
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (4/12) · Qty limit (11/12)
Tradjenta
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Glyxambi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (4/8) · Qty limit (6/8)
Tradjenta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Glyxambi
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Tradjenta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Glyxambi.
No savings programs available for Tradjenta.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
GlyxambiView full Glyxambi profile
TradjentaView full Tradjenta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.